Depressive Disorder, Treatment-Resistant: all 472 studies

Page 3 of 5. Open to participants first (151), then studies with results posted, then the rest; newest registration first within each.

• A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionCompletedNCT02493868Phase 3Results posted
• Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)CompletedNCT02452892Not applicableResults posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionCompletedNCT02422186Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT02418585Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT02417064Phase 3Results posted
• Efficacy of Repeated Ketamine Infusions for Treatment-resistant DepressionCompletedNCT02360280Phase 2Results posted
• 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in FemalesCompletedNCT02356107Phase 4Results posted
• rTMS in Treatment Resistant DepressionCompletedNCT02080507Not applicableResults posted
• Ketamine in Adolescents With Treatment-Resistant DepressionCompletedNCT02078817Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionCompletedNCT01998958Phase 2Results posted
• Low Field Magnetic Stimulation for Treatment Resistant DepressionCompletedNCT01944644Not applicableResults posted
• Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)CompletedNCT01920555Phase 2Results posted
• Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant DepressionTerminatedNCT01913535Phase 2Results posted
• Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)CompletedNCT01898429Not applicableResults posted
• Ketamine Plus Lithium in Treatment-Resistant DepressionCompletedNCT01880593Phase 2Results posted
• A Study of Olanzapine and Fluoxetine for Treatment-resistant DepressionTerminatedNCT01687478Phase 3Results posted
• Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant DepressionCompletedNCT01654796Not applicableResults posted
• A Study of Ketamine in Patients With Treatment-resistant DepressionCompletedNCT01627782Phase 2Results posted
• Pharmacogenomics for Antidepressant Guidance and EducationTerminatedNCT01555021Results posted
• An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept AssayCompletedNCT01507155Not applicableResults posted
• Buprenorphine for Treatment Resistant DepressionCompletedNCT01407575Phase 3Results posted
• Radiosurgical Neuromodulation for Refractory DepressionTerminatedNCT01403441Not applicableResults posted
• Intranasal Ketamine in Treatment-Resistant DepressionCompletedNCT01304147Not applicableResults posted
• Efficacy and Tolerability of Riluzole in Treatment Resistant DepressionCompletedNCT01204918Phase 2Results posted
• Treatment Resistant Depression (Pilot)CompletedNCT01179009Not applicableResults posted
• Buprenorphine for Late-Life Treatment Resistant DepressionCompletedNCT01071538Phase 2Results posted
• PET Biomarkers in Treatment Resistant DepressionTerminatedNCT01031810Phase 4Results posted
• A Study in Relapse Prevention of Treatment-Resistant DepressionCompletedNCT00958568Phase 3Results posted
• Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant DepressionCompletedNCT00953745Not applicableResults posted
• Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant DepressionCompletedNCT00837486Phase 2Results posted
• Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD PatientsCompletedNCT00789854Phase 3Results posted
• Optimization of IV Ketamine for Treatment Resistant DepressionCompletedNCT00768430Phase 2Results posted
• Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory DepressionCompletedNCT00608543Phase 4Results posted
• Epidural Cortical Stimulation for DepressionActive, not recruitingNCT00565617Not applicableResults posted
• A Study of Infliximab for Treatment Resistant Major DepressionCompletedNCT00463580Phase 4Results posted
• Treatment-Resistant Depression RegistryCompletedNCT00320372Results posted
• Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different DosesCompletedNCT00305565Phase 4Results posted
• Mifepristone in Refractory DepressionCompletedNCT00186056Not applicableResults posted
• Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant DepressionCompletedNCT00093847Phase 2Results posted
• iTBS Versus Standard 10 Hz rTMS for Treatment-Resistant Depression (TRD)Active, not recruitingNCT07852065Not applicable
• Brain Connectivity and Inflammatory Markers During Short-Term Psychotherapy for Treatment-Resistant DepressionCompletedNCT07847242Not applicable
• Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive DisorderCompletedNCT07804979Not applicable
• Ketamine Biomarker ValidationWithdrawnNCT07307768Phase 1
• Stereotactic Radiotherapy Treatment for Treatment-Resistant DepressionCompletedNCT07274917Not applicable
• 2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy RecommendationCompletedNCT07097025
• MBCT and Escitalopram for Treatment-Resistant Depression in Older AdultsCompletedNCT07077291Not applicable
• A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant DepressionCompletedNCT07053345Phase 4
• Multiple Ascending Dose Phase 1 Study of ALA-3000CompletedNCT06965569Phase 1
• Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major DepressionCompletedNCT06953362
• Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed PatientsCompletedNCT06783361Not applicable
• Psilocybin for Treatment-Resistant Depression in AutismActive, not recruitingNCT06731621Phase 1
• Dose-Optimized and Spaced Transcranial Direct Current Stimulation for Treatment-Resistant DepressionCompletedNCT06730841Not applicable
• Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.CompletedNCT06729580Not applicable
• A Multiple Case Study of Schema Therapy for Difficult-to-treat Depression- DEPRE-ST*CaseCompletedNCT06655623Not applicable
• Effect of Psilocybin on the Positive Valence System in Treatment-resistant DepressionCompletedNCT06650800Not applicable
• Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar DepressionActive, not recruitingNCT06506019Phase 1
• Combining rTMS and tDCS in Depression: an Exploratory Clinical TrialTerminatedNCT06500533Not applicable
• i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical TrialActive, not recruitingNCT06480500Phase 2
• Behavioural Activation Therapy and Esketamine for Resistant DepressionTerminatedNCT06431386Not applicable
• Mindfulness Engaged Neurostimulation for DepressionActive, not recruitingNCT06399406Phase 2
• Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD PatientsCompletedNCT06372834Not applicable
• Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of PsilocybinActive, not recruitingNCT06341426Phase 2
• Psilocybin-Assisted Therapy in Treatment-Resistant DepressionActive, not recruitingNCT06303739Phase 3
• Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)Active, not recruitingNCT06236711Not applicable
• Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant DepressionCompletedNCT06232291
• Psilocybin for Treatment-Resistant DepressionCompletedNCT06230757Phase 2
• Intensive Accelerated iTBS for the Treatment-Resistant DepressionCompletedNCT06166082Not applicable
• Ketogenic Diet for Treatment-Resistant Depression: Dietary Interventions for MEntal Health Study (DIME)CompletedNCT06091163Not applicable
• Open Label - Personalized Therapeutic Neuromodulation for Anhedonic DepressionActive, not recruitingNCT06052137Not applicable
• Low-Intensity Focused Ultrasound for Treatment-Resistant DepressionSuspendedNCT06013384Not applicable
• Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for DepressionActive, not recruitingNCT06002204
• First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)WithdrawnNCT05921929Phase 1
• Exercise to Augment TMS in Those With Treatment Resistant DepressionCompletedNCT05913401Not applicable
• Synaptic Imaging and Network Activity in Treatment Resistant DepressionCompletedNCT05870501Not applicable
• Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II DisorderActive, not recruitingNCT05849402Not applicable
• pBFS Guided High-dose rTMS Therapy for Treatment-Resistant DepressionSuspendedNCT05842291Not applicable
• Dasatinib Plus Quercetin for Accelerated Aging in Mental DisordersActive, not recruitingNCT05838560Phase 2
• Open Label Optimization StudyActive, not recruitingNCT05819021
• Glutamate Emotion Memory StudyStatus unknownNCT05809609Not applicable
• A Trial of GH001 in Patients With Treatment-resistant DepressionCompletedNCT05800860Phase 2
• Specialized Pro-resolving Lipid Mediators and Treatment Resistant DepressionActive, not recruitingNCT05774665Phase 2
• Deep Brain Stimulation for Treatment Resistant DepressionStatus unknownNCT05716555Not applicable
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDActive, not recruitingNCT05711940Phase 3
• N2O for Acute Suicidality and Depression in the EDWithdrawnNCT05710887Phase 2
• Does Psilocybin Require Psychedelic Effects to Treat Depression?CompletedNCT05710237Phase 2
• Predictors of Intravenous Ketamine Response in TRDActive, not recruitingNCT05625555Phase 3
• Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDCompletedNCT05624268Phase 3
• Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for DepressionCompletedNCT05615948Phase 4
• Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRICompletedNCT05598931
• Psilocybin-assisted Interpersonal Therapy for DepressionCompletedNCT05581797Not applicable
• RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)CompletedNCT05531591Phase 4
• The RAFT ECT StudyCompletedNCT05402657Not applicable
• Treatment for Major Depressive Disorder With Intermittent Theta-burst StimulationStatus unknownNCT05390593Not applicable
• TBS Treatment for Treatment-Resistant DepressionCompletedNCT05388539Not applicable
• Antidepressant Effects of Nitrous OxideWithdrawnNCT05357040Phase 2
• An Intervention Study of Anhedonia and Pain Empathy in DepressionStatus unknownNCT05355142Not applicable
• A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionWithdrawnNCT05268497Phase 1
• The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationCompletedNCT05220410Phase 2
• A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant DepressionCompletedNCT05196971Phase 1
• Accelerated TBS in Late Life DepressionStatus unknownNCT05119699Not applicable

← Depressive Disorder, Treatment-Resistant overview